Reprieve Cardiovascular Revolutionizes Heart Failure Treatment with $42M Funding

Reprieve Cardiovascular, a Milford, MA-based company, secures $42M in Series A funding to advance intelligent fluid management for heart failure patients. Led by Lightstone Ventures and Sante Ventures, the funding will propel Reprieve's mission to improve patient outcomes and reduce hospital readmissions. With over 6.7 million Americans suffering from heart failure, Reprieve's personalized approach aims to address this critical need by continuously monitoring patients' physiological parameters and adjusting diuretic dosing accordingly. The company's innovative technology offers potential benefits such as improved patient outcomes, reduced hospital readmissions, and enhanced patient comfort. Currently conducting the FASTR Trial, Reprieve plans to launch a pivotal trial soon, utilizing the funding to refine their technology and prepare for commercialization. CEO Mark Pacyna emphasizes the importance of intelligent decongestion management in providing physicians and care teams with added visibility and control throughout treatment. Reprieve Cardiovascular's groundbreaking therapies are set to revolutionize heart failure treatment for millions worldwide.